drugset / Trial / NCT03970200
Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).
Timeline
- Start
- 2020-01-16
- Primary completion
- 2021-11-21
- Completion
- 2022-05-14
Outcome
Outcome not reported
Stopped: “Administrative reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Penn Microbiome Therapy - 001 | Unknown | — | Rectal |
| Subject | Penn Microbiome Therapy - 002 | Unknown | — | Oral |
| Subject | Penn Microbiome Therapy - 003 | Unknown | — | Oral |